EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, 3SBio,'s Enterprise Value is €556.3 Mil.
3SBio,'s EBIT for the trailing twelve months (TTM) ended in Dec. 2016 was €135.9 Mil. Therefore, 3SBio,'s EV-to-EBIT for today is 4.09.
The historical rank and industry rank for 3SBio,'s EV-to-EBIT or its related term are showing as below:
FRA:YFK'
s EV-to-EBIT Range Over the Past 10 Years
Min: 4.47 Med: 24.6 Max: 33.6
Current: 4.47
During the past 13 years, the highest EV-to-EBIT of 3SBio, was 33.60. The lowest was 4.47. And the median was 24.60.
FRA:YFK's EV-to-EBIT is not ranked
in the Biotechnology industry.
Industry Median: 9.84
vs FRA:YFK: 4.47
The historical data trend for 3SBio,'s EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, 3SBio,'s EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
3SBio,'s EV-to-EBIT Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 3SBio,'s EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where 3SBio,'s EV-to-EBIT falls into.
3SBio,'s current Enterprise Value is €556.3 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. 3SBio,'s EBIT for the trailing twelve months (TTM) ended in Dec. 2016 was €135.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
3SBio, (FRA:YFK) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
3SBio,'s Enterprise Value for the quarter that ended in Dec. 2016 was €0.0 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. 3SBio,'s EBIT for the trailing twelve months (TTM) ended in Dec. 2016 was €135.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
3SBio, EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of 3SBio,'s EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
3SBio Inc is engaged in the healthcare sector based in China. It is a pharmaceutical products company and its core activities pertain to developing, manufacturing and marketing biopharmaceuticals. Its portfolio of products comprises of TPIAO and Yisaipu. TPIAO is the only commercialized recombinant human thrombopoietin (rhTPO) product in the world and Yisaipu is a TNF inhibibator product and accounts for the major share in the pharmaceutical industry in China. Most of the company's activities are focused on China while having a minor footprint in a foreign land.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:YFK has been successfully added to your 